CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B‑cell acute lymphoblastic leukemia (ALL) that has come back or not responded to at least one round of chemotherapy (or a targeted drug if you have a particular gene change).
- Your leukemia cells must have the CD19 protein on them if you've had a prior CD19‑targeted treatment.
- You must be at least 12 years old (the first few patients need to be 17 or older).
- Your organs (liver, kidneys, lungs, and heart) must be working well enough, and you should be up and doing most of your daily activities (ECOG 0‑1 or Lansky ≥60).
- You cannot have active leukemia in your brain or spinal cord that is causing symptoms or visible on scans, or certain other active cancers, serious autoimmune diseases, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Hear when a new Philadelphia-Positive ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.